Stock listing
NASDAQ:MRVI Maravai LifeSciences Holdings, Inc. Stock
Home listing (NASDAQ) of Maravai LifeSciences Holdings, Inc.
Follow Maravai LifeSciences Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MRVI
$6.98 USD -0.40 (-5.4%)
Close on Nov 20, 2026
- Day range
- $6.91 – $7.17 USDNov 20, 2026
- Volume
- 1.79M sharesNov 20, 2026
- Market cap
- $1.04B USDAt the close on Nov 20, 2026 · price × 149.0M shares outstanding
- 52-week range
- $2.80 – $9.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $22.78M USDMedian day 2.37M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MRVI · Home | $6.98 USD | -0.40 (-5.4%) | 1,785,366 | $7.11 | $7.17 | $6.91 | $7.38 | Close on Nov 20, 2026 |
| Frankfurt:MAR | €6.35 EUR | -0.15 (-2.3%) | — | €6.40 | €6.40 | €6.30 | €6.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MRVI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.98 | -0.40 | -5.4% | $7.11 | $7.17 | $6.91 | 1,785,366 | |
| $7.38 | +0.10 | +1.4% | $7.28 | $7.54 | $7.21 | 1,408,255 | |
| $7.28 | -0.12 | -1.6% | $7.36 | $7.53 | $7.175 | 1,609,035 | |
| $7.40 | -0.14 | -1.9% | $7.45 | $7.60 | $7.09 | 1,512,884 | |
| $7.54 | -0.14 | -1.8% | $7.73 | $7.75 | $7.385 | 1,992,204 | |
| $7.68 | -0.02 | -0.3% | $7.93 | $7.93 | $7.60 | 2,503,526 | |
| $7.70 | -0.16 | -2.0% | $7.96 | $8.18 | $7.68 | 2,036,769 | |
| $7.86 | -0.16 | -2.0% | $7.87 | $8.01 | $7.62 | 1,745,450 | |
| $8.02 | +0.50 | +6.6% | $7.53 | $8.16 | $7.495 | 2,146,613 | |
| $7.52 | +0.54 | +7.7% | $7.02 | $7.62 | $7.02 | 1,936,351 | |
| $6.98 | -0.74 | -9.6% | $6.85 | $7.57 | $6.80 | 3,211,753 | |
| $7.72 | +0.27 | +3.6% | $7.73 | $7.89 | $7.28 | 3,619,529 | |
| $7.45 | +0.26 | +3.6% | $7.33 | $7.75 | $7.33 | 1,903,718 | |
| $7.19 | -0.62 | -7.9% | $7.81 | $7.99 | $7.155 | 2,292,419 | |
| $7.81 | -0.65 | -7.7% | $8.37 | $8.48 | $7.68 | 1,703,904 | |
| $8.46 | -0.04 | -0.5% | $8.49 | $8.62 | $8.29 | 1,384,941 | |
| $8.50 | +0.24 | +2.9% | $8.23 | $8.525 | $8.15 | 2,712,370 | |
| $8.26 | +0.68 | +9.0% | $7.60 | $8.28 | $7.50 | 3,068,338 | |
| $7.58 | +0.26 | +3.6% | $7.32 | $7.60 | $7.32 | 1,268,559 | |
| $7.32 | +0.25 | +3.5% | $7.03 | $7.33 | $6.98 | 1,447,700 | |
| $7.07 | -0.50 | -6.6% | $7.44 | $7.61 | $6.73 | 3,920,300 | |
| $7.57 | +0.37 | +5.1% | $7.18 | $7.615 | $7.18 | 1,699,800 | |
| $7.20 | +0.21 | +3.0% | $6.99 | $7.595 | $6.985 | 2,022,500 | |
| $6.99 | +0.20 | +2.9% | $6.79 | $7.02 | $6.69 | 1,349,400 | |
| $6.79 | -0.28 | -4.0% | $7.05 | $7.08 | $6.735 | 2,238,700 | |
| $7.07 | +0.52 | +7.9% | $6.70 | $7.15 | $6.51 | 2,367,100 | |
| $6.55 | +0.02 | +0.3% | $6.41 | $6.67 | $6.334 | 2,742,500 | |
| $6.53 | -0.53 | -7.5% | $6.95 | $7.06 | $6.52 | 4,326,200 | |
| $7.06 | -0.38 | -5.1% | $7.38 | $7.381 | $6.95 | 1,253,200 | |
| $7.44 | +0.23 | +3.2% | $7.25 | $7.52 | $7.17 | 2,304,500 | |
| $7.21 | -0.22 | -3.0% | $7.31 | $7.37 | $7.01 | 3,593,800 | |
| $7.43 | -0.42 | -5.4% | $7.65 | $7.73 | $7.22 | 4,272,700 | |
| $7.85 | -0.67 | -7.9% | $8.54 | $8.74 | $7.765 | 3,613,100 | |
| $8.52 | +0.62 | +7.8% | $8.015 | $8.575 | $7.80 | 2,629,000 | |
| $7.90 | +0.40 | +5.3% | $7.62 | $7.92 | $7.50 | 1,913,600 | |
| $7.50 | -0.16 | -2.1% | $7.67 | $7.73 | $7.325 | 4,340,000 | |
| $7.66 | +0.01 | +0.1% | $7.65 | $7.75 | $7.53 | 3,606,300 | |
| $7.65 | +0.02 | +0.3% | $7.52 | $7.70 | $7.435 | 1,755,500 | |
| $7.63 | +0.03 | +0.4% | $7.49 | $7.68 | $7.40 | 1,942,300 | |
| $7.60 | -0.05 | -0.7% | $7.61 | $7.65 | $7.245 | 1,930,300 | |
| $7.65 | +0.28 | +3.8% | $7.35 | $7.76 | $7.31 | 2,392,700 | |
| $7.37 | -0.09 | -1.2% | $7.42 | $7.48 | $7.13 | 1,549,300 | |
| $7.46 | +0.29 | +4.0% | $7.18 | $7.49 | $6.985 | 1,571,000 | |
| $7.17 | +0.20 | +2.9% | $7.00 | $7.235 | $6.92 | 2,300,100 | |
| $6.97 | -0.30 | -4.1% | $7.20 | $7.24 | $6.825 | 2,518,400 | |
| $7.27 | +0.43 | +6.3% | $6.98 | $7.515 | $6.98 | 3,446,200 | |
| $6.84 | -0.04 | -0.6% | $6.90 | $7.089 | $6.78 | 3,080,900 | |
| $6.88 | +0.195 | +2.9% | $6.68 | $7.00 | $6.63 | 2,676,800 | |
| $6.685 | +0.155 | +2.4% | $6.53 | $6.81 | $6.53 | 2,260,100 | |
| $6.53 | -0.20 | -3.0% | $6.84 | $6.91 | $6.485 | 3,263,000 | |
| $6.73 | -0.22 | -3.2% | $6.81 | $6.89 | $6.66 | 3,325,000 | |
| $6.95 | -0.24 | -3.3% | $7.08 | $7.16 | $6.925 | 2,206,700 | |
| $7.19 | -0.13 | -1.8% | $7.30 | $7.32 | $7.10 | 2,272,700 | |
| $7.32 | -0.05 | -0.7% | $7.25 | $7.435 | $7.17 | 1,552,100 | |
| $7.37 | -0.01 | -0.1% | $7.38 | $7.455 | $7.212 | 2,908,000 | |
| $7.38 | +0.08 | +1.1% | $7.30 | $7.605 | $7.27 | 3,668,100 | |
| $7.30 | -0.34 | -4.5% | $7.58 | $7.59 | $7.28 | 2,698,300 | |
| $7.64 | -0.04 | -0.5% | $7.71 | $7.725 | $7.52 | 5,318,000 | |
| $7.68 | -0.69 | -8.2% | $8.12 | $8.175 | $7.645 | 5,563,000 | |
| $8.37 | -0.53 | -6.0% | $8.76 | $8.98 | $8.325 | 3,171,000 | |
| $8.90 | -0.10 | -1.1% | $8.85 | $9.42 | $8.68 | 5,537,600 | |
| $9.00 | +0.57 | +6.8% | $8.53 | $9.06 | $8.34 | 5,695,900 | |
| $8.43 | -0.21 | -2.4% | $8.59 | $8.615 | $8.13 | 6,964,200 | |
| $8.64 | +0.35 | +4.2% | $8.28 | $8.87 | $8.20 | 9,390,900 | |
| $8.29 | +1.07 | +14.8% | $7.44 | $8.378 | $7.38 | 13,145,900 |
- Ticker
- NASDAQ:MRVI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
Latest earnings call · Nov 4, 2026
Maravai LifeSciences Holdings (NASDAQ:MRVI) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 28 slides
Latest news
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
Nov 4, 2026
Closed $6.98 (-9.6%) on Nov 5, 2026
Maravai LifeSciences Announces November 2026 Investor Conference Schedule
Oct 29, 2026
Closed $7.81 (-7.7%) on Oct 30, 2026
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
Oct 14, 2026
Closed $7.07 (+7.9%) on Oct 15, 2026
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $6.23 (-0.3%) on Aug 7, 2026
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
Jul 22, 2026
Closed $7.05 (-0.7%) on Jul 23, 2026
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
Jul 20, 2026
Closed $7.10 (+1.6%) on Jul 21, 2026
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
Jun 16, 2026
Closed $5.01 (+1.0%) on Jun 16, 2026
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Jun 3, 2026
Closed $4.84 (+0.2%) on Jun 3, 2026
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
May 18, 2026
Closed $4.22 (+3.4%) on May 19, 2026
Maravai LifeSciences Reports First Quarter 2026 Financial Results
May 7, 2026
Closed $4.85 (+23.1%) on May 8, 2026
Maravai LifeSciences Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 13 in the last 12 months · 131 in all · newest Nov 4, 2026 · oldest 2020
- Calls
- 18 calls with a replay · 18 with a transcript · latest Nov 4, 2026
- Decks
- 26 decks · latest Nov 4, 2026
Where Maravai LifeSciences Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MRVI · Home listing · This page | NASDAQ | United States | USD |
| BMV:MRVI | BMV | Mexico | MXN |
| LS Exchange:A2QHK8 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2QHK8 | Lang & Schwarz | Germany | EUR |
| Stuttgart:MAR | Stuttgart | Germany | EUR |
| Frankfurt:MAR | Frankfurt | Germany | EUR |
| BOATS:MRVI | BOATS | United States | USD |
| Dusseldorf:MAR | Dusseldorf | Germany | EUR |
| Tradegate:MAR | Tradegate | Germany | EUR |
| BIVA:MRVI | BIVA | Mexico | MXN |
Valuation
EV/sales 5.2× against a median of 3.8×: 7th lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.11B USD
- P/E
- Loss
- EV/sales
- 5.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.3×
- Gross margin
- 39.1%
- Operating margin
- −45.4%
- Net margin
- −30.8%
- Debt to equity
- 0.8×
- Beta vs S&P 500
- 1.56
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVI | US$1.04B | US$1.11B | n/a | 5.2× | n/a | 5.3× | −30.8% | 0.8× | 1.56 |
| Vcanbio Cell & Gene Engineering Corp., Ltd. Class A · SSE:600645 | US$1.06B | US$786.1M | 62.8× | 3.8× | n/a | 1.9× | 8.2% | 0.0× | n/a |
| Beijing Strong Biotechnologies Inc Class A · SZSE:300406 | US$1.05B | US$1.13B | 28.0× | 5.5× | n/a | 1.9× | 18.2% | 0.3× | n/a |
| Freenome, Inc. · NASDAQ:FRNM | US$1.04B | US$863.3M | 9.5× | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137 | US$1.02B | US$909.1M | n/a | 38.0× | n/a | 3.4× | −60.8% | 0.0× | n/a |
| Castle Biosciences, Inc. · NASDAQ:CSTL | US$1.01B | US$745.1M | n/a | 2.0× | n/a | 2.1× | −6.1% | 0.0× | 1.00 |
| Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482 | US$1.01B | US$785.0M | n/a | 2.7× | n/a | 1.2× | −3.2% | 0.0× | n/a |
| St Pharm Co., Ltd. · KRX:237690 | US$992.7M | US$866.0M | 17.4× | 3.0× | 11.1× | 2.1× | 19.9% | 0.0× | n/a |
| Daan Gene Co., Ltd. Class A · SZSE:002030 | US$990.1M | US$810.9M | n/a | 7.0× | n/a | 0.9× | −95.7% | 0.0× | n/a |
| Amoy Diagnostics Co., Ltd. Class A · SZSE:300685 | US$967.3M | US$801.3M | 18.8× | 4.4× | n/a | 3.3× | 28.5% | 0.1× | n/a |
| Novogene Co., Ltd. Class A · SSE:688315 | US$949.6M | US$685.6M | 43.1× | 2.0× | n/a | 2.3× | 6.4% | 0.0× | n/a |
| Median of the others | US$1.01B | US$806.1M | 23.4× | 3.8× | 11.1× | 2.1× | 6.4% | 0.0× | 1.00 |
Forecasts
6 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.64 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.070 · 9 analysts
- Revenue, year to Dec 2026
- 214.3M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Bernd Brust | Chief Executive Officer and Board Member |
| Raj Asarpota | EVP, Chief Financial Officer |
| Kurt Oreshack | EVP, Secretary and General Counsel |
| Andrew Murphy | Vice President, General Manager, Glen Research |
| Chad Decker | Senior Vice President, Sales, TriLink and Alphazyme |
| Chanfeng Zhao | Senior Vice President, Chief Scientific Officer |
| Christine Dolan | EVP, Biologics Safety Testing |
| Davide De Lucrezia | Senior Vice President, Digital Innovation, Products & Marketing |
| Elie Chaaya | Senior Vice President, TriLink Global Operations |
| Judy Solecki | Chief Human Resources Officer |
Board
| Director | Role |
|---|---|
| Andy Eckert | Chairman of the Board |
| Bernd Brust | Chief Executive Officer and Board Member |
| Constantine Mihas | Director |
| Gregory T. Lucier | Director |
Events
- Next results
- Feb 24, 2027 (expected)
Calls
All 18 calls
| Call | When | Status |
|---|---|---|
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q2 2023 Earnings Call | Mon, Aug 07, 2023 · 4:05 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q1 2023 Earnings Call | Mon, May 08, 2023 · 5:00 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q4 2022 Earnings Call | Wed, Feb 22, 2023 · 5:00 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q3 2022 Earnings Call | Wed, Nov 02, 2022 · 5:00 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q1 2022 Earnings Call | Thu, May 05, 2022 · 5:00 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q4 2021 Earnings Call | Wed, Feb 23, 2022 · 5:00 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 5:00 PM ET | Replay |
| Maravai LifeSciences Holdings (NASDAQ:MRVI) Q1 2021 Earnings Call | Mon, May 10, 2021 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −9.6% |
| Q2 2026 | Aug 6, 2026 · After close | −0.3% |
| Q1 2026 | May 7, 2026 · After close | +23.1% |
| Q4 2025 | Feb 25, 2026 | +14.1% |
| Q3 2025 | Nov 6, 2025 · After close | −0.7% |
| Q2 2025 | Aug 11, 2025 · After close | +30.6% |
| Q1 2025 | May 12, 2025 · After close | −2.8% |
| Q4 2024 | Feb 20, 2025 · After close | +4.0% |
| Q3 2024 | Nov 7, 2024 · After close | −35.3% |
| Q2 2024 | Aug 7, 2024 · After close | −6.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +11.2% |
| Q4 2023 | Feb 22, 2024 · After close | +63.6% |
| Q3 2023 | Nov 7, 2023 · After close | −31.7% |
| Q2 2023 | Aug 7, 2023 · After close | +0.7% |
| Q1 2023 | May 8, 2023 · After close | −13.0% |
| Q4 2022 | Feb 22, 2023 · After close | +8.2% |
| Q3 2022 | Nov 2, 2022 · After close | −5.5% |
| Q2 2022 | Aug 4, 2022 · After close | +2.3% |
| Q1 2022 | May 5, 2022 · After close | +13.4% |
| Q4 2021 | Feb 23, 2022 · After close | −1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 28 slides | Nov 4, 2026 |
| Investor Presentation (November 2026) | Investor deck | 27 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 27 slides | September 2026 |
| Q2 2026 Earnings Presentation | Earnings | 26 slides | Aug 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 25 slides | May 7, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 24 slides | Feb 25, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 22 slides | Nov 6, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 21 slides | Aug 11, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 25 slides | May 12, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 25 slides | Mar 20, 2025 |
All 26 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2024 Earnings Presentation | Earnings | 24 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 30 slides | Aug 7, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 25 slides | May 8, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 31 slides | Feb 22, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 26 slides | Nov 7, 2023 |
| Investor Day (September 2023) | Investor day | 152 slides | September 2023 |
| Investor Day (September 2023) | Investor day | 150 slides | September 2023 |
| Q2 2023 Earnings Presentation | Earnings | 25 slides | Aug 7, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 31 slides | May 8, 2023 |
| Q4 2022 Earnings Presentation | Earnings | 33 slides | Feb 22, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 26 slides | Nov 2, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 29 slides | Aug 4, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 26 slides | May 5, 2022 |
| Q4 2021 Earnings Presentation | Earnings | 27 slides | Feb 23, 2022 |
| Investor Day (January 2022) | Investor day | 74 slides | Jan 28, 2022 |
| Q3 2021 Earnings Presentation | Earnings | 28 slides | Nov 10, 2021 |
IPO
Priced at US$27.00 a share on Nov 19, 2020.
- Price
- US$27.00 a share
- Shares offered
- 60,000,000 shares of Class A common stock
- Offering size
- US$1.62 billion
- Underwriters' option
- Up to 9,000,000 more shares
- Underwriters
- MORGAN STANLEY, JEFFERIES, GOLDMAN SACHS & CO. LLC, BOFA SECURITIES, CREDIT SUISSE, UBS INVESTMENT BANK, BAIRD, WILLIAM BLAIR, STIFEL, KEYBANC CAPITAL MARKETS, ACADEMY SECURITIES, LOOP CAPITAL MARKETS, PENSERRA SECURITIES LLC, TIGRESS FINANCIAL PARTNERS · In the order on the cover
- Shares delivered
- On or about Nov 24, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 8, 2020 |
| Filed publicly | Oct 29, 2020 |
| Amended twice | Newest Nov 13, 2020 |
| Shares registered with an exchange | Nov 19, 2020 |
| Declared effective by the SEC | Nov 19, 2020 |
| Final prospectus, with the price | Nov 23, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 23, 2020 |
| EFFECT · Notice that a registration is effective | Nov 19, 2020 |
| S-1MEF · Registration of more shares for the same offering | Nov 19, 2020 |
| CERT · Exchange's certificate of listing | Nov 19, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 19, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| S-1/A · Registration statement, amended | Nov 13, 2020 |
| CORRESP · Letter to the SEC | Nov 9, 2020 |
| S-1/A · Registration statement, amended | Nov 9, 2020 |
All 22 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 6, 2020 |
| UPLOAD · Letter from the SEC | Nov 3, 2020 |
| CORRESP · Letter to the SEC | Oct 29, 2020 |
| S-1 · Registration statement | Oct 29, 2020 |
| UPLOAD · Letter from the SEC | Oct 28, 2020 |
| DRSLTR · Letter to the SEC with a draft | Oct 23, 2020 |
| DRS/A · Draft registration statement, amended | Oct 23, 2020 |
| UPLOAD · Letter from the SEC | Oct 21, 2020 |
| DRSLTR · Letter to the SEC with a draft | Oct 14, 2020 |
| DRS/A · Draft registration statement, amended | Oct 14, 2020 |
| UPLOAD · Letter from the SEC | Oct 8, 2020 |
| DRS · Draft registration statement | Sep 8, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 23, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 185.7M | 259.2M | 288.9M | 883.0M | 799.2M | 284.1M | 143.1M | 123.8M |
| Cost of revenue | 151.8M | 150.9M | 148.7M | 169.0M | 140.6M | 79.6M | 66.8M | 60.8M |
| Gross profit | 34.0M | 108.3M | 140.2M | 714.0M | 658.7M | 204.4M | 76.3M | 63.1M |
| Research and development | 17.4M | 19.2M | 17.3M | 18.4M | 15.2M | 9.30M | 3.63M | 4.50M |
| Selling, general and administrative | 145.1M | 161.8M | 151.4M | 129.3M | 100.1M | 94.2M | 48.4M | 41.2M |
| Operating income | -215.3M | -235.6M | -31.6M | 574.2M | 554.6M | 119.9M | 24.0M | 16.4M |
| Depreciation and amortization | 23.6M | 20.9M | 12.9M | 7.57M | 6.41M | 5.59M | 3.81M | 22.3M |
| EBITDA | -191.7M | -214.8M | -18.8M | 581.8M | 561.1M | 125.5M | 27.8M | 38.8M |
| Interest expense | 27.0M | 47.7M | 45.9M | 20.4M | 30.3M | 30.7M | 30.0M | 27.4M |
| Income before tax | -235.0M | -261.5M | 617.7M | 551.5M | 530.8M | 81.7M | -5.85M | -16.5M |
| Income tax | -4.21M | -1.86M | 756.1M | 60.8M | 61.5M | 2.88M | -652.0K | 417.0K |
| Net income | -130.8M | -144.8M | -119.0M | 220.2M | 182.0M | 89.0M | -4.47M | -17.7M |
| Earnings per share, basic | -0.90 | -1.05 | -0.90 | 1.67 | 1.59 | 7.43 | -0.03 | -0.20 |
| Earnings per share, diluted | -0.90 | -1.05 | -0.90 | 1.67 | 1.56 | 2.36 | -0.03 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 216.9M | 322.4M | 575.0M | 632.1M | 551.3M | 236.2M | 24.7M | 21.9M |
| Receivables | 25.5M | 38.5M | 54.6M | 138.6M | 117.5M | 51.0M | 18.0M | 16.0M |
| Inventory | 40.5M | 50.1M | 51.4M | 43.2M | 51.6M | 33.3M | 14.2M | 14.3M |
| Current assets | 296.3M | 429.1M | 699.9M | 847.9M | 740.0M | 331.6M | 60.6M | 53.8M |
| Property, plant and equipment | 151.5M | 164.5M | 162.9M | 52.7M | 46.3M | 101.3M | 94.3M | 42.6M |
| Goodwill | 129.4M | 159.9M | 326.0M | 283.7M | 152.8M | 224.3M | 224.3M | 224.3M |
| Total assets | 770.6M | 1.01B | 1.49B | 2.28B | 1.92B | 1.27B | 577.8M | 539.7M |
| Accounts payable | 2.91M | 12.0M | 10.7M | 5.99M | 8.15M | 8.17M | 7.48M | 3.60M |
| Current liabilities | 44.9M | 57.0M | 87.5M | 110.1M | 93.8M | 130.8M | 29.6M | 35.9M |
| Long-term debt | 286.3M | 290.5M | 518.7M | 522.0M | 524.6M | 528.6M | 334.8M | 335.6M |
| Total debt | 291.8M | 295.9M | 524.1M | 527.4M | 530.6M | 534.6M | 390.2M | 339.9M |
| Total liabilities | 397.9M | 431.0M | 697.6M | 1.38B | 1.37B | 1.12B | 433.2M | 391.7M |
| Shareholders' equity | 212.4M | 325.3M | 416.8M | 545.2M | 315.5M | 88.5M | 144.6M | 144.4M |
| Shares outstanding | 145.1M | 137.9M | 131.9M | 131.7M | 122.0M | 96.6M | 96.6M | 89.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -57.6M | 7.46M | 126.2M | 536.0M | 368.6M | 152.2M | 24.1M | -186.0K |
| Capital spending | -13.1M | -29.7M | -65.6M | -17.1M | -14.8M | -25.4M | -17.1M | -3.61M |
| Free cash flow | -70.7M | -22.2M | 60.7M | 518.9M | 353.7M | 126.8M | 6.97M | -3.80M |
| Cash from investing | -31.4M | -24.3M | -122.3M | -267.6M | 105.7M | 6.07M | -17.1M | -3.45M |
| Cash from financing | -16.5M | -235.7M | -61.1M | -187.5M | -159.0M | 53.2M | -4.17M | -9.17M |
| Dividends paid | -153.5M | -609.3M | -97.1M | -52.1M | ||||
| Share buybacks | -2.08M | -20.0K | 0 | 0 | -33.7M | 0 | -9.00K | |
| Change in cash | -105.5M | -252.6M | -57.2M | 80.9M | 315.1M | 211.5M | 2.83M | -12.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2026 | Material contract | SEC |
| 8-K · Current report | May 29, 2026 | Meeting outcome | SEC |
| 4/A · Change in ownership, amended | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 31, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 27, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 18, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 8-K · Current report | May 28, 2025 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | May 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 18, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| NT 10-K · Late filing notice | Mar 4, 2025 | Explanation request | SEC |
| 8-K · Current report | Feb 24, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Feb 20, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 31, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2025 | Results | SEC |
| 8-K · Current report | Dec 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 17, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 12, 2024 | Material contract | SEC |
| CORRESP · Letter to the SEC | Aug 16, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 8-K · Current report | Jul 29, 2024 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Jul 19, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jun 24, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 12, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 11, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Jun 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2024 | Other filings | SEC |
| 8-K · Current report | May 28, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | May 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 28, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 22, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 15, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
This page holds 200 of 426 filings. Open Filings
Cap table
Built by 6ix from Maravai LifeSciences Holdings, Inc.’s releases
- Common shares
- 148,989,545
- Fully diluted
- 148,989,545
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 148,989,545 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 148,989,545 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gregory T. Lucier Other companies: Avantor, Inc. (Director · Since at least Oct 3, 2025); Dentsply Sirona Inc. (Non-Executive Chairman of the Board · Since at least May 22, 2019); Berkeley Lights Inc (Director · Jul 16, 2020 – May 26, 2022 · Past); Invuity Inc (Director · Jun 11, 2015 – Oct 23, 2018 · Past); Catalent Inc (Director · Apr 30, 2015 – Dec 18, 2024 · Past); NuVasive Inc (Director · Dec 4, 2013 – May 18, 2021 · Past); CareFusion Corp (Director · Aug 31, 2009 – Mar 17, 2015 · Past) | Director · Since at least Nov 19, 2020 |
| Susannah Gray Other companies: AnaptysBio, Inc. (Member of the Audit Committee · Since at least Mar 26, 2026); Theravance Biopharma, Inc. (Director · Since at least Feb 26, 2023); 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Apria Inc (Director · May 4, 2021 – Mar 29, 2022 · Past); Morphic Holding Inc (Director · Apr 27, 2021 – Aug 16, 2024 · Past) | Director · Since at least Nov 19, 2020 |
| Jessica Hopfield Other companies: Editas Medicine, Inc. (Chair · Since at least Feb 14, 2018); Insulet Corporation (Director · Since at least Jul 27, 2015); Berkeley Lights Inc (Director · Dec 15, 2021 – May 26, 2022 · Past); Radius Health, Inc. (Director · Jan 24, 2019 – Feb 20, 2020 · Past) | Director · Since at least Nov 19, 2020 |
| Anat Ashkenazi Other companies: Alphabet Inc (Google) Class C (SVP, Chief Financial Officer · Since at least Jul 31, 2024); Eli Lilly and Company (EVP & CFO · Feb 8, 2021 – Feb 12, 2024 · Past); Varian Medical Systems Inc (Director · Dec 1, 2018 – Apr 15, 2021 · Past) | Director · Nov 19, 2020 – May 23, 2024 · Past |
| John DeFord Other companies: Globus Medical, Inc. (Director · Since at least Sep 1, 2023); Nordson Corporation (Chairman, Chief Executive Officer and President · Since at least Nov 23, 2020); NuVasive Inc (Director · Feb 26, 2018 – Sep 1, 2023 · Past) | Director · Since at least Jul 20, 2023 |
| Rajesh Asarpota Other companies: Profusa, Inc. (Director · Since at least Jul 11, 2025); NuVasive Inc (CFO · Sep 1, 2017 – Mar 1, 2019 · Past); Questcor Pharmaceuticals Inc (Sr. VP., CFO and PAO · Feb 17, 2014 – Aug 14, 2014 · Past) | Chief Financial Officer · Since at least Jun 30, 2025 |
| R. Andrew Eckert Other companies: Becton, Dickinson and Company (Director · Since at least Sep 26, 2016); Fortrea Holdings Inc. (Director · Jun 29, 2023 – Feb 21, 2025 · Past); Varian Medical Systems Inc (Director · Feb 3, 2012 – Feb 11, 2021 · Past) | Director · Since at least Dec 5, 2024 |
| Carl Hull Other companies: Ortho Clinical Diagnostics Holdings plc (Director · Jan 27, 2021 – May 27, 2022 · Past); Hologic Inc (SVP and GM of Diagnostics · Aug 1, 2012 – Feb 1, 2013 · Past) | See Remarks, Director · Nov 19, 2020 – Nov 11, 2024 · Past |
| Christine Dolan Other companies: Catalent Inc (SVP - Product Development · Sep 8, 2016 – Aug 29, 2017 · Past) | EVP, Biologics Safety Testing · Since at least Nov 19, 2020 |
| Constantine Mihas Other companies: Sotera Health Company (Director · Nov 20, 2020 – May 22, 2025 · Past) | Director · Since at least Nov 19, 2020 |
All 33 people
| Person | Seat |
|---|---|
| Kevin Herde Other companies: Sorrento Therapeutics, Inc. (Executive VP and CFO · Apr 5, 2016 – Feb 3, 2017 · Past) | Chief Financial Officer · Nov 19, 2020 – May 15, 2025 · Past |
| Peter Michael Leddy Other companies: NuVasive Inc (EVP, People and Culture · Jul 27, 2011 – Aug 1, 2018 · Past) | See Remarks · Since at least Jun 27, 2022 |
| Robert B Hance Other companies: Abbott Laboratories (Senior Vice President · Dec 11, 2006 – Feb 29, 2012 · Past) | Director · Nov 19, 2020 – Nov 19, 2021 · Past |
| Sean Laurence Cunningham Other companies: Sotera Health Company (Director · Since at least Nov 20, 2020) | Director · Since at least Nov 19, 2020 |
| William E Martin III Other companies: Azenta, Inc. (President Multiomics · Since at least Apr 6, 2026) | Chief Executive Officer · Sep 30, 2022 – Mar 17, 2025 · Past |
| Andrew Burch | See Remarks · Mar 31, 2023 – Jan 15, 2025 · Past |
| Andrew Murphy | Vice President, General Manager, Glen Research · Since at least Nov 4, 2026 |
| Andy Eckert | Chairman of the Board · Since at least May 28, 2026 |
| Benjamin James Daverman | Director · Since at least Nov 19, 2020 |
| Bernd Brust | Chief Executive Officer and Board Member · Since at least Jun 8, 2025 |
| Brian Neel | See Remarks · Nov 19, 2020 – Feb 15, 2023 · Past |
| Chad Decker | Senior Vice President, Sales, TriLink and Alphazyme · Since at least Jun 16, 2026 |
| Chanfeng Zhao | Senior Vice President, Chief Scientific Officer · Since at least Jul 20, 2026 |
| Davide De Lucrezia | Senior Vice President, Digital Innovation, Products & Marketing · Since at least Feb 24, 2025 |
| Elie Chaaya | Senior Vice President, TriLink Global Operations · Since at least Nov 4, 2026 |
| Eric Tardif | President · Nov 19, 2020 – Nov 19, 2020 · Past |
| Judy Solecki | Chief Human Resources Officer · Since at least Nov 4, 2026 |
| Kurt Oreshack | EVP, Secretary and General Counsel · Since at least Nov 19, 2020 |
| Lisa Sellers | See Remarks · Nov 19, 2020 – Nov 24, 2020 · Past |
| Luke Joseph Marker | Director · Since at least Nov 19, 2020 |
| Murali Prahalad | Director · Since at least Nov 19, 2020 |
| Raj Asarpota | EVP, Chief Financial Officer · Since at least Oct 29, 2026 |
| Rebecca Buzzeo | See Remarks · Mar 31, 2023 – Mar 17, 2025 · Past |
Log in to ask 6ix AI your own questions about Maravai LifeSciences Holdings, Inc.